Abstract：OBJECTIVE China is still in its infancy in assessing the value of anti-tumor drugs, lacking a mature drug value assessment system. To provide reference for the establishment of a pharmacoeconomic model based on value assessment in China, and provide valuable reference for clinicians and patients to choose treatment options, Through the analysis and discussion of the DrugAbacus interactive calculator. METHODS The value components and data sources of the DrugAbacus interactive calculator were analyzed by literature search, data query, etc., and the price of the anti-tumor drugs was evaluated according to the baseline values. RESULTS The actual price of anti-cancer drug afinitor is higher than the recommended price when used to treat kidney cancer, pancreatic cancer and breast cancer. When the anti-tumor drug avastin is used in the treatment of colon cancer, the actual price is not much different from the recommended price. Halaven′s suggested price is always higher than the actual price, that is, the price of the drug is at least reasonable or even low, and Ixempra′s price is high, so using the drug Halaven can save more money than using the drug Ixempra. CONCLUSION The DrugAbacus method provides a complex analysis of the factors that should be considered in drug pricing. Although there are limitations, this method reflects to a large extent the evaluation of the value of innovative drugs in society, which can provide reference for drug pricing in China.
SCHNIPPER L E. American society of clinical oncology statement:a conceptual framework to assess the value of cancer treatment options[J]. J Clin Oncol, 2015, 33(23):2563-2577.
[2]
KIM C, PRASAD V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival:an analysis of 5 years of US Food and Drug Administration approvals[J]. JAMA Intern Med, 2015,175(12):1992-1994.
[3]
Meizhongyaoyuan.Life is no longer priceless: The American Society of Clinical Oncology (ASCO) has released the "Value Framework" of anticancer drugs "(value framework)[EB/OL].[2018-01-08]. http://www.biodiscover.com/news/politics/120048.html.
[4]
WESTRICH K, BUELT L, DUBOIS R W. Why value framework assessments arrive at different conclusions: a multiple myeloma case study[J]. J Manag Care Spec Pharm,2017,23(6-a Suppl):28-33.
[5]
Memorial Sloan Kettering Cancer Center Drug Pricing Lab. Methods. http:// drugpricinglab.org/tools/drug-abacus/methods/#faqs. 2017-06-08.
[6]
COOPER K, SMITH H J, LEATH C A, et al. Using DrugAbacus to determine the value of PD-1 inhibitors in ovarian cancer:how much should they cost?[J]. Gynecol Oncol, 2017,145:165.
[7]
SMITH H J, COOPER K, LEATH C A, et al. Using value-based tools to determine the value of bevacizumab in cer-vicaland ovarian cancer[J]. Gynecol Oncol, 2017,145:62-63.
[8]
XIA X M, FDA approved Halaven (eribulin mesylate) for the treatment of liposarcoma [J]. J Guangdong Univ Pharmacy (广东药学院学报),,2016,32(01):110.
[9]
HOU Y W. Drug Abacus——New Pricing Scheme for Anticancer Drugs EB/OL]. (2018-10-29)[2015-06-25].https://news.yaozh.com/archive/8236.html.
[10]
PETER B. Bach. A New Way to Define Value in Drug Pricing[EB/OL].[2018-01-08].https://catalyst.nejm.org/a-new-way-to-define-value-in-drug-pricing/.
2019, Vol. 54 
